Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Roland Martinꝉ, Bruno Gran, Yingdong Zhao, Silva Markovic‐Plese, Bibiana Bielekova, Adriana R. Marques, Myong‐Hee Sung, Richard M Simon, Henry F. McFarland, Clemencia Pinilla
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
Immunological aspects of demyelinating diseases
10.1146/annurev.iy.10.040192.001101 · 1992
Axonal transection in the lesions of multiple sclerosis
10.1056/nejm199801293380502 · 1998
Multiple sclerosis
10.1056/nejm200009283431307 · 2000
On the immunopathology of plaque development and repair in multiple sclerosis
10.1016/0165-5728(88)90160-9 · 1988
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination
10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q · 2000
Escape from “horror autotoxicus”: pathogenesis and treatment of autoimmune disease
10.1016/0092-8674(95)90443-3 · 1995
Animal models
10.1002/ana.410360714 · 1994
The T lymphocyte in experimental allergic encephalomyelitis
10.1146/annurev.iy.08.040190.003051 · 1990
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group
10.1038/ng0896-469 · 1996
A full genome search in multiple sclerosis
10.1038/ng0896-472 · 1996
Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic aminoacid sequences
10.1016/0198-8859(89)90074-8 · 1989
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
10.1038/ng0896-464 · 1996
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
10.1038/80516 · 2000
Clinical viral infections and multiple sclerosis
10.1016/s0140-6736(85)92801-6 · 1985
Chickenpox and multiple sclerosis: a case report
10.1136/jnnp.58.5.637-a · 1995
Amino Acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity
10.1126/science.2414848 · 1985
Virus-induced autoimmune demyelinating disease of the central nervous system. Chapter 24
1986
Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein
10.1016/0092-8674(95)90348-8 · 1995
ζ phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
10.1126/science.7824949 · 1995
Tickling the TCR: Selective T-Cell Functions Stimulated by Altered Peptide Ligands
10.1016/0167-5699(93)90200-5 · 1993
Essential flexibility in the T cell recognition of antigen
10.1038/380495a0 · 1996
Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone
10.1084/jem.185.9.1651 · 1997
Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells
10.4049/jimmunol.158.8.3746 · 1997
T cell receptor antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology
10.4049/jimmunol.160.8.3631 · 1998
Identification of candidate epitopes and molecular mimics in chronic Lyme disease
10.1038/70946 · 1999
Probing degeneracy in T-cell recognition using combinatorial peptide libraries
10.1016/s0167-5699(97)01217-6 · 1998
Exploring immunological specificity using synthetic peptide combinatorial libraries
10.1016/s0952-7915(99)80033-8 · 1999
Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency
10.4049/jimmunol.164.2.861 · 2000
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
10.1038/9858 · 1999
Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection
10.1126/science.279.5355.1344 · 1998
In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis
10.1084/jem.188.9.1725 · 1998
Measles encephalomyelitis: Clinical and immunological studies
10.1056/nejm198401193100301 · 1984
Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
10.1126/science.1833816 · 1991
Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor
10.1016/0092-8674(92)90139-4 · 1992
Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling
10.1084/jem.177.4.1047 · 1993
Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy
10.1016/0092-8674(94)90080-9 · 1994
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production
10.1084/jem.180.6.2227 · 1994
Dynamics of autoimmune T cell infiltration: reversal of paralysis and disappearance of inflammation following treatment of experimental encephalomyelitis with a myelin basic protein peptide analog
10.1038/379343a0 · 1996
An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
10.1016/1074-7613(95)90169-8 · 1995
A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevents experimental autoimmune encephalomyelitis induced by multiple myelin antigens
10.1073/pnas.94.17.9279 · 1997
NBI-5788, an altered MBP 83–99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients
10.1002/1531-8249(200011)48:5<758::aid-ana9>3.0.co;2-2 · doi-reference
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
10.1038/80525 · doi-reference
Human T-cell response to myelin basic protein peptide (83–99): Extensive heterogeneity in antigen recognition, function, and phenotype
10.1212/wnl.49.4.1116 · doi-reference
Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99)
10.1002/eji.1830261113 · doi-reference
Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating disease
10.1111/j.1600-065x.1995.tb00071.x · doi-reference
Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming
10.1038/8444 · doi-reference
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants
10.1038/369403a0 · doi-reference
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells
10.1038/369407a0 · doi-reference